Linezolid for the treatment of drug-resistant tuberculosis
- PMID: 40846488
- DOI: 10.1183/13993003.00927-2025
Linezolid for the treatment of drug-resistant tuberculosis
Conflict of interest statement
Conflict of interest: C. Lange reports support for the present study from German Center of Infection Research, consultancy fees from INSMED, honoraria for lectures, presentations, manuscript writing or educational events outside the scope of this work from INSMED, GILEAD, AstraZeneca and GSK, and participation on a data safety board with Medicines Sans Frontiers. C. Barry III reports support for the present study from the Intramural Research Program of the National Institute of Allergy and Infectious Disease, part of NIH, DHHS, US Federal Government. G. Sotgiu reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events outside the scope of this work from INSMED, Pfizer, AstraZeneca and Qiagen. He acts as a Statistics Editor for this journal.
Comment on
-
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis.Eur Respir J. 2025 Aug 22;66(2):2500315. doi: 10.1183/13993003.00315-2025. Print 2025 Aug. Eur Respir J. 2025. PMID: 40675768 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources